Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Biogen Inc shares valued at $69,045 were sold by Singhal Priya on Sep 02 ’25. At $133.55 per share, Singhal Priya sold 517 shares. The insider’s holdings dropped to 5,772 shares worth approximately $0.83 million following the completion of this transaction.
Also, Singhal Priya purchased 517 shares, netting a total of over 69,045 in proceeds.
Before that, Izzar Rachid had sold 2,223 shares from its account. In a trade valued at $300,105, the Head of Global Product Strat. traded Biogen Inc shares for $135.00 each. Upon closing the transaction, the insider’s holdings decreased to 2,223 shares, worth approximately $0.91 million.
As published in their initiating research note from Jefferies on September 25, 2025, Biogen Inc [BIIB] has been a Buy and the price target has been revised to $190. As of April 28, 2025, HSBC Securities has decreased its “Buy” rating to a “Hold” for BIIB. Earlier on April 04, 2025, Argus downgraded its rating. Their new recommendation was “a Hold” for BIIB stock which previously was a “a Buy”.
Analyzing BIIB Stock Performance
On last trading session, Biogen Inc [NASDAQ: BIIB] plunged -1.14% to $143.66. The stock’s lowest price that day was $142.3, but it reached a high of $145.185 in the same session. During the last five days, there has been a drop of approximately -4.84%. Over the course of the year, Biogen Inc shares have dropped approximately -23.74%.
Is Biogen Inc subject to short interest?
Stocks of Biogen Inc saw a sharp rise in short interest on 2025-09-30 jumping by 0.16 million shares to 4.88 million. Data from Yahoo Finance shows that the short interest on 2025-08-29 was 4.72 million shares. A jump of 3.26% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 2.9 of the overall float, the days-to-cover ratio (short ratio) jumped to 2.9.
Which companies own the most shares of Biogen Inc (BIIB)?
In terms of Biogen Inc share price expectations, FactSet research, analysts set an average price target of 188.5 in the next 12 months, up nearly 29.72% from the previous closing price of $145.31. Analysts anticipate Biogen Inc stock to reach 213 by 2025, with the lowest price target being 118. In spite of this, 32 analysts ranked Biogen Inc stock as Buy at the end of 2025. On February 11, 2025, Bernstein assigned a price target of “a Mkt perform” to the stock and initiated coverage with a $160.
